BFBrendan T. Freitas

Brendan T. Freitas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brendan T. Freitas has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiplex Detection of Immunoglobulins Uncovers Intrathecal IgA Elevation in Multiple Sclerosis

    by Leonard Apeltsin, Sakthi Asokan, Brendan Freitas, Krish Karekar, Samuel Guzman, Enrique Alvarez, Xiaoli Yu

    Background: Intrathecal IgG synthesis is a well-established hallmark of multiple sclerosis (MS), yet the roles of other immunoglobulin isotypes remain under investigated. This study aimed to comprehensively profile immunoglobulin distributions in cerebrospinal fluid (CSF) and plasma from MS patients and neurological controls. Methods: Paired CSF and plasma samples from 23 MS patients and 20 neurological controls were analyzed using a multiplex Luminex-based immunoassay targeting IgG1–4, IgA, and IgM. The findings were validated using commercial ELISA kits and Western blot analysis. Results: Multiplex analysis revealed a selective intrathecal enrichment of IgA and IgM in MS CSF, with significantly higher levels compared to both matched plasma and control CSF. IgG1 was modestly elevated in MS CSF by ELISA but not by multiplex assay. Western blotting confirmed a robust elevation of IgA in MS CSF, providing qualitative support for intrathecal enrichment rather than definitive proof of synthesis. Conclusions: These findings uncover previously underappreciated selective enrichment of IgA and IgM in the MS CNS compartment, complementing, rather than replacing, the established IgG-centric paradigm. The results suggest alternative antibody-mediated mechanisms in MS and highlight the importance of assay selection in biomarker discovery, which suggests IgA as an emerging component of MS immunopathology.

  • Open Access

    Losartan promotes cell survival following SARS-CoV-2 infection in vitro

    by Reza Nejat, Ahmad Shahir Sadr, Brendan T. Freitas, Jackelyn Crabtree, Scott D. Pegan, Ralph A. Tripp, David J. Najafi

    Introduction Coronavirus disease 2019 (COVID-19) can be associated with mortality and high morbidity worldwide. There is an extensive effort to control infection and disease caused by SARS-CoV-2. This study addressed the hypothesis that angiotensin II type I receptor blocker, Losartan, may restrict pathogenesis caused by SARS-CoV-2 by decreasing viral-induced cytopathological changes by blocking angiotensin II type 1 receptor (AT1R), thus reducing the affinity of the virus for ACE2, and inhibiting papain-like protease of the virus. Method Losartan inhibitory effect on deubiquitination and deISGylation properties of papain-like protease was investigated using a fluorescence method and gel shift analysis determining its inhibitory effects. The inhibitory effect of Losartan on SARS-CoV-2 cell replication was investigated both when losartan was added to the cell culture 1 hour before (pre-infection group) and 1 hour after (post-infection group) SARS-CoV-2 infection of Vero E6 cells. Results Losartan treatment of Vero E6 cells prior to and after SARS-CoV-2 infection reduced SARS-CoV-2 replication by 80% and 70% respectively. Losartan was not a strong deubiquitinase and deISGylase inhibitor of PLpro. Conclusion Losartan added pre- and post-infection to the Vero E6 cell culture significantly prevents cell destruction and replication by SARS-CoV2. Losartan has low side-effects, is readily available, and can be produced at high levels globally, all features of a promising drug in treatment of COVID-19 if validated by clinical trials.


  • Flipping the substrate preference of Hazara virus ovarian tumour domain protease through structure-based mutagenesis

    by John V. Dzimianski, Savannah L. Mace, Isabelle L. Williams, Brendan T. Freitas, Scott D. Pegan

    Nairoviruses are arthropod-borne viruses with a nearly global geographical distribution. Several are known causative agents of human disease, including Crimean–Congo hemorrhagic fever virus (CCHFV), which has a case fatality rate that can exceed 30%. Nairoviruses encode an ovarian tumour domain protease (OTU) that can suppress the innate immune response by reversing post-translational modifications by ubiquitin (Ub) and/or interferon-stimulated gene product 15 (ISG15). As a result, the OTU has been identified as a potential target for the development of CCHFV therapeutics. Despite sharing the same general fold, nairoviral OTUs show structural and enzymatic diversity. The CCHFV OTU, for example, possesses activity towards both Ub and ISG15, while the Hazara virus (HAZV) OTU interacts exclusively with Ub. Virology studies focused on the OTU have mostly been restricted to CCHFV, which requires BSL-4 containment facilities. Although HAZV has been proposed as a BSL-2 alternative, differences in the engagement of substrates by CCHFV and HAZV OTUs may present complicating factors when trying to model one using the other. To understand the molecular underpinnings of the differences in activity, a 2.78 Å resolution crystal structure of HAZV OTU bound to Ub was solved. Using structure-guided site-directed mutagenesis, HAZV OTUs were engineered with altered or eliminated deubiquitinase activity, including one with an exclusive activity for ISG15. Additionally, analysis of the structure yielded insights into the difference in inhibition observed between CCHFV and HAZV OTUs with a Ub-based inhibitor. These new insights present opportunities to utilize HAZV as a model system to better understand the role of the OTU in the context of infection.


  • Open Access

    Determining the molecular drivers of species-specific interferon-stimulated gene product 15 interactions with nairovirus ovarian tumor domain proteases

    by John V Dzimianski, Florine E M Scholte, Isabelle L Williams, Caroline Langley, Brendan T Freitas, Jessica R Spengler, Éric Bergeron, Scott D Pegan

    Tick-borne nairoviruses (order Bunyavirales) encode an ovarian tumor domain protease (OTU) that suppresses the innate immune response by reversing the post-translational modification of proteins by ubiquitin (Ub) and interferon-stimulated gene product 15 (ISG15). Ub is highly conserved across eukaryotes, whereas ISG15 is only present in vertebrates and shows substantial sequence diversity. Prior attempts to address the effect of ISG15 diversity on viral protein-ISG15 interactions have focused on only a single species’ ISG15 or a limited selection of nairovirus OTUs. To gain a more complete perspective of OTU-ISG15 interactions, we biochemically assessed the relative activities of 14 diverse nairovirus OTUs for 12 species’ ISG15 and found that ISG15 activity is predominantly restricted to particular nairovirus lineages reflecting, in general, known virus-host associations. To uncover the underlying molecular factors driving OTUs affinity for ISG15, X-ray crystal structures of Kupe virus and Ganjam virus OTUs bound to sheep ISG15 were solved and compared to complexes of Crimean-Congo hemorrhagic fever virus and Erve virus OTUs bound to human and mouse ISG15, respectively. Through mutational and structural analysis seven residues in ISG15 were identified that predominantly influence ISG15 species specificity among nairovirus OTUs. Additionally, OTU residues were identified that influence ISG15 preference, suggesting the potential for viral OTUs to adapt to different host ISG15s. These findings provide a foundation to further develop research methods to trace nairovirus-host relationships and delineate the full impact of ISG15 diversity on nairovirus infection.


  • Open Access

    Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice

    by Florine E. M. Scholte, Jessica R. Spengler, Stephen R. Welch, Jessica R. Harmon, JoAnn D. Coleman-McCray, Brendan T. Freitas, Markus H. Kainulainen, Scott D. Pegan, Stuart T. Nichol, Éric Bergeron, et al.

    (2019). Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. Emerging Microbes & Infections: Vol. 8, No. 1, pp. 575-578.


  • Open Access

    Data-Driven Prediction of CRISPR-Based Transcription Regulation for Programmable Control of Metabolic Flux

    by Jiayuan Sheng, Weihua Guo, Christine Ash, Brendan Freitas, Mitchell Paoletti, Xueyang Feng

    Multiplex and multi-directional control of metabolic pathways is crucial for metabolic engineering to improve product yield of fuels, chemicals, and pharmaceuticals. To achieve this goal, artificial transcriptional regulators such as CRISPR-based transcription regulators have been developed to specifically activate or repress genes of interest. Here, we found that by deploying guide RNAs to target on DNA sites at different locations of genetic cassettes, we could use just one synthetic CRISPR-based transcriptional regulator to simultaneously activate and repress gene expressions. By using the pairwise datasets of guide RNAs and gene expressions, we developed a data-driven predictive model to rationally design this system for fine-tuning expression of target genes. We demonstrated that this system could achieve programmable control of metabolic fluxes when using yeast to produce versatile chemicals. We anticipate that this master CRISPR-based transcription regulator will be a valuable addition to the synthetic biology toolkit for metabolic engineering, speeding up the “design-build-test” cycle in industrial biomanufacturing as well as generating new biological insights on the fates of eukaryotic cells.